Japan's Ministry of Health, Labour and Welfare has approved the extension of the present marketing authorisation for United States-based Alexion Pharmaceuticals' SOLIRIS to include the prevention of relapse in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica, it was reported yesterday.
The SOLIRIS approval was based on comprehensive results from the Phase three randomised, double-blind placebo controlled PREVENT trial, which were published in The New England Journal of Medicine and a long-term extension study (ECU-NMO-302), which is still underway.
The product was approved for the treatment of NMOSD in adult patients who are anti-AQP4 antibody-positive by the United States Food and Drug Administration (FDA) in June 2019 and by the European Commission (EC) in August 2019. The product received Orphan Drug Designation for the treatment of NMOSD in the US, EU and Japan.
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder